Cyclophosphamide is a chemotherapy and immunosuppressant drug. It is often used as an adjuvant drug with other chemotherapy medications especially for leukemia and lymphomas. (These cancers include Hodgkin’s and non-Hodgkin's lymphoma, Burkitt’s lymphoma, chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), acute myelocytic leukemia (AML), acute lymphocytic leukemia (ALL), t-cell lymphoma (mycosis fungoides), multiple myeloma, neuroblastoma, retinoblastoma, rhabdomyosarcoma, Ewing's sarcoma; breast, testicular, endometrial, ovarian, and lung cancers, and in conditioning regimens for bone marrow transplantation.)
Theory[edit | edit source]
Evidence[edit | edit source]
Norwegian Study - Cyclo/ME[edit | edit source]
There is no evidence for the use of the drug to treat ME/CFS.
A Norwegian group, led by the researchers, Dr. Øystein Fluge and Professor Olav Mella, who are studying Rituximab use in ME/CFS, are running a clinical trial, called CycloME. The trial will test the effects of cyclophosphamide on ME/CFS patients that have been non-responders to Rituximab.
Risks & safety[edit | edit source]
Costs & availability[edit | edit source]
Learn more[edit | edit source]
See also[edit | edit source]
References[edit | edit source]
- Clinical Trials - Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS) (CycloME)
Myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.